Patents by Inventor Hans-Juergen Woerle

Hans-Juergen Woerle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190038654
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 7, 2019
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190015437
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: March 12, 2018
    Publication date: January 17, 2019
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN
    Publication number: 20190000855
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 3, 2019
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Michael MARK, Hans-Juergen WOERLE, Heike ZIMDAHL-GELLING
  • ANTIDIABETIC MEDICATIONS
    Publication number: 20180344741
    Abstract: Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Inventors: Eva GRAEFE-MODY, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180318251
    Abstract: The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: Uli Christian BROEDL, Afshin SALSALI, Hans-Juergen WOERLE
  • Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
    Patent number: 10092571
    Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: October 9, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
  • TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
    Publication number: 20180271859
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 27, 2018
    Inventors: Klaus DUGI, Eva Ulrike GRAEFE-MODY, Ruth HARPER, Hans-Juergen WOERLE
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20180263990
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE
  • Treatment for diabetes in patients inappropriate for metformin therapy
    Patent number: 10034877
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 31, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Ruth Harper, Hans-Juergen Woerle
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180200278
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Inventors: Uli Christian BROEDL, Sreeraj MACHA, Maximilian von EYNATTEN, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180169126
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 21, 2018
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180125813
    Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 10, 2018
    Inventors: Maximilian von EYNATTEN, Uli Christian BROEDL, Hans-Juergen WOERLE
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 9949998
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 9949997
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG
    Publication number: 20170368068
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Inventors: Eva Ulrike GRAEFE-MODY, Thomas KLEIN, Michael MARK, Hans-Juergen WOERLE
  • VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20170340643
    Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 30, 2017
    Inventors: Thomas KLEIN, Andreas DAIBER, Odd-Erik JOHANSEN, Michael MARK, Sanjaykumar PATEL, Hans-Juergen WOERLE
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20170333465
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 23, 2017
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20170266152
    Abstract: The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 21, 2017
    Inventors: Uli BROEDL, Afshin SALSALI, Hans-Juergen WOERLE
  • ANTIDIABETIC MEDICATIONS
    Publication number: 20170173027
    Abstract: Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.
    Type: Application
    Filed: February 28, 2017
    Publication date: June 22, 2017
    Inventors: Eva GRAEFE-MODY, Hans-Juergen WOERLE
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20170065596
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE